4D Molecular Therapeutics annual total assets
2019
2020
2021
2022
2023
2024
2025
4D Molecular Therapeutics Total Assets Growth & History (FDMT)
4D Molecular Therapeutics's total assets was $566.7M for fiscal 2025.
View full 4D Molecular Therapeutics company overview4D Molecular Therapeutics annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $566.7M | $6.3M | +1.13% |
| 2024 | 2024-12-31 | $560.4M | $220.5M | +64.87% |
| 2023 | 2023-12-31 | $339.9M | $78.0M | +29.81% |
| 2022 | 2022-12-31 | $261.8M | −$91.6M | −25.92% |
| 2021 | 2021-12-31 | $353.5M | $65.2M | +22.60% |
| 2020 | 2020-12-31 | $288.3M | $230.1M | +395.12% |
| 2019 | 2019-12-31 | $58.2M | — | — |
4D Molecular Therapeutics quarterly total assets
Q4.19
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $492.6M | $19.0M | +4.01% |
| Q1 2026 | 2026-03-31 | $512.9M | −$2.8M | −0.55% |
| Q4 2025 | 2025-12-31 | $566.7M | $6.3M | +1.13% |
| Q3 2025 | 2025-09-30 | $424.0M | −$180.0M | −29.81% |
| Q2 2025 | 2025-06-30 | $473.6M | −$146.5M | −23.62% |
| Q1 2025 | 2025-03-31 | $515.7M | −$114.2M | −18.12% |
| Q4 2024 | 2024-12-31 | $560.4M | $220.5M | +64.87% |
| Q3 2024 | 2024-09-30 | $604.0M | $242.4M | +67.04% |
| Q2 2024 | 2024-06-30 | $620.1M | $267.6M | +75.92% |
| Q1 2024 | 2024-03-31 | $629.9M | $385.9M | +158.13% |
| Q4 2023 | 2023-12-31 | $339.9M | $78.0M | +29.81% |
| Q3 2023 | 2023-09-30 | $361.6M | $81.4M | +29.07% |
| Q2 2023 | 2023-06-30 | $352.5M | $49.6M | +16.36% |
| Q1 2023 | 2023-03-31 | $244.0M | −$80.9M | −24.90% |
| Q4 2022 | 2022-12-31 | $261.8M | −$91.6M | −25.92% |
| Q3 2022 | 2022-09-30 | $280.2M | $39.5M | +16.44% |
| Q2 2022 | 2022-06-30 | $302.9M | $48.0M | +18.83% |
| Q1 2022 | 2022-03-31 | $324.9M | $54.8M | +20.29% |
| Q4 2021 | 2021-12-31 | $353.5M | $65.2M | +22.60% |
| Q3 2021 | 2021-09-30 | $240.6M | — | — |
| Q2 2021 | 2021-06-30 | $254.9M | — | — |
| Q1 2021 | 2021-03-31 | $270.1M | — | — |
| Q4 2020 | 2020-12-31 | $288.3M | $230.1M | +395.12% |
| Q4 2019 | 2019-12-31 | $58.2M | — | — |
4D Molecular Therapeutics total assets trends
Over the last five fiscal years, 4D Molecular Therapeutics's total assets increased from $288.3M to $566.7M, a change of $278.4M. The latest reported quarter, Q2 2026, shows $492.6M.
About the metric
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
Calculation and source
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review 4D Molecular Therapeutics source filings ↗